Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Aug 12, 2016
Insider Transaction Report
Form 4
Gullans Steven R. Ph.D.
Director
Transactions
- Conversion
Common Stock
2016-08-10$6.71/sh+306,025$2,052,173→ 306,025 total(indirect: Held by Excel Venture Fund II, L.P.) - Conversion
8% Convertible Subordinated Promissory Note
2016-08-10→ 0 total(indirect: Held by Excel Venture Fund II, L.P.)Exercise: $6.71→ Common Stock (306,025 underlying) - Purchase
Common Stock
2016-08-10$10.00/sh+500,000$5,000,000→ 806,025 total(indirect: Held by Excel Venture Fund II, L.P.)
Footnotes (2)
- [F1]The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F2]The note was issued in the original principal amount of $2,000,000. The outstanding principal and $52,164 of accrued interest on the note automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.